Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy. A team of researchers from the University of Zurich and the Children’s Hospital Zurich successfully achieved this using the ‘gene-scissor’ CRISPR/Cas9 technology. The aim is to treat severely affected patients in the near future using novel approaches.
Chronic Granulomatous Disease is a hereditary disease of the immune system. Due to a gene defect, phagocytes of affected patients are unable to kill ingested bacteria and fungi; causing life-threatening infections and excessive inflammatory reactions that have severe adverse consequences.
The disease can be cured by transplanting blood-forming stem cells from the bone marrow of healthy donors. Where no matching stem cell donor is available, gene therapy can be carried out, in a few locations worldwide. Before gene therapy is used clinically in patients, efficacy of treatment must be determined in the lab on human cells; cellular models are of utmost importance for this step.
Better Cell Model Developed Thanks to 'Gene Scissors'
Recently, a research team headed by Janine Reichenbach, a UZH professor and Co-Head of the Division of Immunology at the University Children’s Hospital Zurich, has developed a new cellular model that enables to test the efficacy of new gene therapies much more efficiently. "We used Crispr/Cas9 technology to change a human cell line so that the blood cells show the genetic change typical of a specific form of Chronic Granulomatous Disease", explains the pediatrician and immunologist.
In this way, the modified cells reflect the disease genetically and functionally. Until now, scientists had to rely on using patients' skin cells that they had reprogrammed into stem cells in the lab. This approach is laborious, and requires considerable time and money. "With our new testing system, this process is faster and cheaper, enabling us to develop new gene therapies for affected patients more efficiently", says Janine Reichenbach.
Already about ten years ago, the team of Janine Reichenbach initiated the worldwide first clinically successful gene therapy study for the treatment of children with Chronic Granulomatous Disease – headed at that time by UZH's now emeritus Professor Reinhard Seger. The principle was to isolate blood-forming stem cells from the patient's bone marrow, transfer a healthy copy of the diseased gene into these cells in the lab, and infuse the gene-corrected cells back into the blood of the patient. The corrected blood stem cells find their way back to the bone marrow where they engraft and produce healthy immune cells.
New ‘Gene Ferries’ Make Gene Therapy Safer
To transfer the healthy copy of the gene into diseased cells, until now modified artificial viruses have been used as transport vehicle for the correcting genes. Despite curing the primary disease, gene therapies using first generation viral gene correction systems are now outdated, due to the development of malignant cancer cells in some patients in European studies.
Janine Reichenbach's team currently works with a new improved ‘gene ferry’. "Today, we dispose of so-called lentiviral self-inactivating gene therapy systems that are efficient and, above all, that work more safely". The University Children’s Hospital Zurich is one of three European centers able to use this new gene therapy in an international clinical phase I/II study to treat patients with Chronic Granulomatous Disease (EU-FP7 program NET4CGD).
Future of Gene Therapy: Precise Repair of Defective Genes
For Janine Reichenbach's team, such new ‘gene ferries’ are only an intermediate step. In future, gene defects shall no longer be treated by adding a functioning gene using viral ‘gene ferries’, but instead are repaired with pinpoint precision using genome editing. Crispr/Cas9 is key here too.
However, it will need another five to six years until this 'precision gene surgery' is ready for clinical applications. Janine Reichenbach appears optimistic. "Within the framework of University Medicine Zurich, we have the technical, scientific and medical know-how on site to develop new therapies for patients with severe hereditary diseases faster and establish UZH as an international competence center of excellence for gene and cell therapies in the future."
Dominik Wrona, Ulrich Siler, Janine Reichenbach. CRISPR/Cas9-generated p47phox-deficient cell line for Chronic Granulomatous Disease gene therapy vector development. Scientific Reports. March 13, 2017. DOI: 10.1038/srep44187
Prof. Janine Reichenbach, M.D.
University Children’s Hospital Zurich
Phone: + 41 44 266 73 11
Kurt Bodenmüller | Universität Zürich
HD-Mikroskopie in Millisekunden
20.09.2019 | Universität Bielefeld
Alpenflora im Klimawandel: Pflanzen reagieren mit "Verspätung"
20.09.2019 | Universität Wien
How long the battery of your phone or computer lasts depends on how many lithium ions can be stored in the battery's negative electrode material. If the battery runs out of these ions, it can't generate an electrical current to run a device and ultimately fails.
Materials with a higher lithium ion storage capacity are either too heavy or the wrong shape to replace graphite, the electrode material currently used in...
Heidelberger Wissenschaftler und Ärzte beschreiben aktuell im Fachjournal „Nature“, wie Nervenzellen des Gehirns mit aggressiven Glioblastomen in Verbindung treten und so das Tumorwachstum fördern / Mechanismus der Tumor-Aktivierung liefert Ansatzpunkte für klinische Studien
Nervenzellen geben ihre Signale über Synapsen – feine Zellausläufer mit Kontaktknöpfchen, die der nächsten Nervenzelle aufliegen – untereinander weiter....
To process information, photons must interact. However, these tiny packets of light want nothing to do with each other, each passing by without altering the...
Ein Forschungsteam vom Max-Planck-Institut für Struktur und Dynamik der Materie (MPSD), der Universität Hamburg und dem European Molecular Biology Laboratory (EMBL) hat eine neue Methode entwickelt, um Biomoleküle bei der Arbeit zu beobachten. Sie macht es bedeutend einfacher, enzymatische Reaktionen auszulösen, da hierzu ein Cocktail aus kleinen Flüssigkeitsmengen und Proteinkristallen angewandt wird. Ab dem Zeitpunkt des Mischens werden die Proteinstrukturen in definierten Abständen bestimmt. Mit der dadurch entstehenden Zeitraffersequenz können nun die Bewegungen der biologischen Moleküle abgebildet werden.
Die Funktionen von Biomolekülen werden nicht nur durch ihre molekularen Strukturen, sondern auch durch deren Veränderungen bestimmt. Mittels der...
Researchers from the Department of Atomically Resolved Dynamics of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg, the University of Hamburg and the European Molecular Biology Laboratory (EMBL) outstation in the city have developed a new method to watch biomolecules at work. This method dramatically simplifies starting enzymatic reactions by mixing a cocktail of small amounts of liquids with protein crystals. Determination of the protein structures at different times after mixing can be assembled into a time-lapse sequence that shows the molecular foundations of biology.
The functions of biomolecules are determined by their motions and structural changes. Yet it is a formidable challenge to understand these dynamic motions.
20.09.2019 | Veranstaltungen
20.09.2019 | Veranstaltungen
19.09.2019 | Veranstaltungen
20.09.2019 | Energie und Elektrotechnik
20.09.2019 | Biowissenschaften Chemie
20.09.2019 | Medizintechnik